|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics. CA Cancer
J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ren JS, Shi JF, Zhang HZ, Liu Q, Zhang YM,
Zou SM, Zhang K and Dai M: Preliminary analysis of the colorectal
cancer screening among urban populations in China, 2012–2013.
Zhonghua Yu Fang Yi Xue Za Zhi. 49:441–443. 2015.(In Chinese).
PubMed/NCBI
|
|
3
|
Ge HL: Tumor immunityPrinciples of
immunology. Zhou GY: Shanghai Scientific and Technical Publishers;
Shanghai: pp. 279–294. 2007
|
|
4
|
Bernal M, Ruiz-Cabello F, Concha A,
Paschen A and Garrido F: Implication of the β2-microglobulin gene
in the generation of tumor escape phenotypes. Cancer Immunol
Immunother. 61:1359–1371. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kloor M, Michel S and von Knebel Doeberitz
M: Immune evasion of microsatellite unstable colorectal cancers.
Int J Cancer. 127:1001–1010. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu K: Role of apoptosis resistance in
immune evasion and metastasis of colorectal cancer. World J
Gastrointest Oncol. 2:399–406. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sträter J, Hinz U, Hasel C, Bhanot U,
Mechtersheimer G, Lehnert T and Möller P: Impaired CD95 expression
predisposes for recurrence in curatively resected colon carcinoma:
Clinical evidence for immunoselection and CD95L mediated control of
minimal residual disease. Gut. 54:661–665. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang LY, Lin YC, Mahalingam J, Huang CT,
Chen TW, Kang CW, Peng HM, Chu YY, Chiang JM, Dutta A, et al:
Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of
CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res.
72:1092–1102. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Houston AM, Michael-Robinson JM, Walsh MD,
Cummings MC, Ryan AE, Lincoln D, Pandeya N, Jass JR, Radford-Smith
GL and O'Connell J: The ‘Fas counterattack’ is not an active mode
of tumor immune evasion in colorectal cancer with high-level
microsatellite instability. Hum Pathol. 39:243–250. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ryan AE, Shanahan F, O'Connell J and
Houston AM: Fas ligand promotes tumor immune evasion of colon
cancer in vivo. Cell Cycle. 5:246–249. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pryczynicz A, Guzińska-Ustymowicz K and
Kemona A: Fas/FasL expression in colorectal cancer. An
immunohistochemical study. Folia Histochem Cytobiol. 48:425–429.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bossard C, Bézieau S, Matysiak-Budnik T,
Volteau C, Laboisse CL, Jotereau F and Mosnier JF: HLA-E/β2
microglobulin overexpression in colorectal cancer is associated
with recruitment of inhibitory immune cells and tumor progression.
Int J Cance. 131:855–863. 2012. View Article : Google Scholar
|
|
13
|
Levy EM, Sycz G, Arriaga JM, Barrio MM,
von Euw EM, Morales SB, González M, Mordoh J and Bianchini M:
Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E
membrane expression in colon cancer cells. Innate Immun. 15:91–100.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dukes CE: The surgical pathology of rectal
cancer: President's Address. Proc R Soc Med. 37:131–144.
1944.PubMed/NCBI
|
|
15
|
Sandel MH, Speetjens FM, Menon AG,
Albertsson PA, Basse PH, Hokland M, Nagelkerke JF, Tollenaar RA,
van de Velde CJ and Kuppen PJ: Natural killer cells infiltrating
colorectal cancer and MHC class I expression. Mol Immunol.
42:541–546. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Menon AG, Tollenaar RA, van de Velde CJ,
Putter H, Janssen-van Rhijn CM, Keijzer R, Fleuren GJ and Kuppen
PJ: p53 and HLA class-I expression are not down-regulated in
colorectal cancer liver metastases. Clin Exp Metastasis. 21:79–85.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Menon AG, Janssen-van Rhijn CM, Morreau H,
Putter H, Tollenaar RA, van de Velde CJ, Fleuren GJ and Kuppen PJ:
Immune system and prognosis in colorectal cancer: A detailed
immunohistochemical analysis. Lab Invest. 84:493–501. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Watson NF, Ramage JM, Madjd Z, Spendlove
I, Ellis IO, Scholefield JH and Durrant LG: Immunosurveillance is
active in colorectal cancer as downregulation but not complete loss
of MHC class I expression correlates with a poor prognosis. Int J
Cancer. 118:6–10. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang D, Stewart TJ, Smith KK, Georgi D,
Abrams SI and Liu K: Downregulation of IFN-gammaR in association
with loss of Fas function is linked to tumor progression. Int J
Cancer. 122:350–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krammer PH: CD95′s deadly mission in the
immune system. Nature. 407:789–795. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhen ZJ, Ling JY, Cai Y, Luo WB and He YJ:
Impact of HLA-E gene polymorphism on HLA-E expression in tumor
cells and prognosis in patients with stage III colorectal cancer.
Med Oncol. 30:4822013. View Article : Google Scholar : PubMed/NCBI
|
